PT - JOURNAL ARTICLE AU - Aasmets, Oliver AU - Taba, Nele AU - Krigul, Kertu Liis AU - Andreson, Reidar AU - Estonian Biobank Research Team AU - Org, Elin TI - Long-term consequences of drug usage on the gut microbiome AID - 10.1101/2024.07.17.24310548 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.17.24310548 4099 - http://medrxiv.org/content/early/2024/07/17/2024.07.17.24310548.short 4100 - http://medrxiv.org/content/early/2024/07/17/2024.07.17.24310548.full AB - Medication usage is a significant contributor to the inter-individual variability in the gut microbiome. However, drugs are often used long-term and repeatedly, a notion yet unaccounted for in microbiome studies, which might lead to underestimating the extent of drug effects. Recently, we and others showed that not only the usage of antibiotics and antidepressants at the time of sampling but also past consumption is associated with the gut microbiome. This effect can be “additive” - the more a drug is used, the stronger the effect on the microbiome. Here, by utilizing electronic health records and the Estonian Microbiome cohort metagenomics dataset (n=2,509), we systematically evaluate the long-term effects of antibiotics and human-targeted medications on the gut microbiome. We show that the past usage of medications is associated with the gut microbiome, and for example, the effects of antibiotics, psycholeptics, antidepressants, proton pump inhibitors, and beta-blockers are detectable several years after usage. Furthermore, by analyzing a subcohort (n=328) with microbiome measured repeatedly, we show that similar changes in the gut microbiome occur after treatment initiation, possibly indicating causal effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Estonian Research Council grants PUT1371 and PRG1414 (to EO), EMBO Installation grant 3573 (to EO), and Biocodex Microbiota Foundation research grant (to EO). EO was supported by European Regional Development Fund Project No. 15-0012 GENTRANSMED and Estonian Center of Genomics/Roadmap II project No 16-0125. KLK was supported by The European Regional Development Fund (Smart specialization PhD scholarship).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the University of Tartu gave ethical approval for this work (No 266-T10). Estonian Committee on Bioethics and Human Research gave ethical approval for this work (No 1.1-12/2768).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes